NCAM1 and neoplasm: In small-cell lung carcinoma, CD47 blocking targets various targets, including CD56 (neural cell adhesion molecule, NCAM), and promotes significant improvement via macrophage-initiated tumour immunities (Weiskopf et al., 2016).